NCT07474051 2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
Clinical Trials
4 trialsNCT04230265 2026-01-22
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT04633148 2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT03031938 2021-06-25
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer
Phase 3 Completed